Daniel I. Goldberg

Cooley advised Aclaris Therapeutics (Nasdaq: ACRS), a clinical-stage biopharmaceutical company developing novel drug candidates for immuno-inflammatory diseases, on its exclusive license agreement with Biosion and $80 million private placement.

Cooley advised long-time biotech client, Gamida Cell Ltd., and its wholly-owned subsidiary, Gamida Cell Inc. (collectively, the “Company”), in the Company’s global restructuring through a novel use of debt arrangement proceedings in Israel combined with Chapter 15 and 11 proceedings in the United States. 

Cooley advised Cidara Therapeutics (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, on its concurrent $240 million private placement financing and definitive agreement with Janssen Pharmaceuticals, a Johnson & Johnson Company, to reacquire the exclusive global development and commercial rights to CD388.

Cooley advised the underwriters in Aura Biosciences’ $86.7 million follow-on offering. SVB Securities, Cowen and Evercore ISI acted as joint bookrunning managers for the offering. Aura is a clinical-stage biotechnology company that is leveraging its novel targeted oncology platform to develop a potential new standard of care across multiple cancer indications, with an initial focus on ocular and urologic oncology. Partners Rich Segal, Div Gupta and Daniel Goldberg led the Cooley team.

Cooley advised the underwriters on Seabridge Gold’s $105.2 million follow-on offering. Seabridge Gold is a development-stage company involved in the evaluation, acquisition, exploration and development of gold properties sited in North America. Partner Daniel Goldberg led the Cooley team.